Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis
Regulatory milestone marks third approval for Soliris in China, further expanding access to rare disease medicines.Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement inhibitor approved for the treatment of gMG in China. The approval by the National Medical Products Administration (NMPA) in China was based on comprehensive results from the Phase III REGAIN trial.[1] In the trial, Soliris demonstrated